Drug Database
BE

benfotiamine + folic acid + benzamine (Zycose)

✓ Approved

Zylera · Small Molecule · Small Molecule

What is benfotiamine + folic acid + benzamine?

benfotiamine + folic acid + benzamine is a small molecule developed by Zylera. It is approved for therapeutic indications via unknown.

Drug Profile

Brand NamesZycose
CompanyZylera
Drug ClassSmall Molecule
RouteUnknown
StatusApproved
Sources: ClinicalTrials.gov, Zylera

Therapeutic Indications

benfotiamine + folic acid + benzamine is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
InvestigationsGlucose tolerance test abnormal✓ Approved

Related Research Articles

PubMedJournal of clinical medicine2026-10-16

Routine Vitamin and Iron Biomarkers Do Not Explain Variation in Anti-Müllerian Hormone: Implications for Ovarian Reserve Testing in Clinical Practice.

Karalök Mete Hakan MH, Dündar Bağnu B, Parmaksız Ayhan A, Elgün Tugba T et al.

Background: Anti-Müllerian hormone (AMH) is a key biomarker of ovarian reserve, reflecting the quantity of the remaining follicular pool. While chronological age is the primary determinant of AMH concentrations, emerging evidence suggests that vitamin D, vitamin B12, folate, and iron metabolism parameters may also influence ovarian function through mechanisms involving steroidogenesis, DNA synthesis, and oxidative stress regulation. However, clinical findings regarding these associations remain inconsistent. Objective: The aim of this study was to evaluate the relationships between serum AMH concentrations and biomarkers of vitamin D status, vitamin B12, folate, ferritin, and lipid profile in women of reproductive age, and to compare the strength of these associations with that of chronological age. Methods: This retrospective, observational, cross-sectional study included 264 women who underwent AMH testing at Atlas University Hospital. Demographic and laboratory data including AMH, age, vitamin D, vitamin B12, folic acid, ferritin, and lipid parameters were extracted from electronic medical records. Bivariate correlations were assessed using Pearson's and Spearman's coefficients on both untransformed and Box-Cox power-transformed data, and were repeated as first-order partial correlations conditioning on chronological age. Statistical significance was set at p < 0.05. Results: The mean age was 34.61 ± 5.75 years, and median AMH was 0.96 ng/mL (Q1-Q3: 0.34-2.34). Age showed a moderate-to-strong, significant inverse correlation with AMH (Pearson's r = -0.508, Spearman's rho = -0.547; p < 0.001), and the linear component of this association strengthened after Box-Cox transformation (Pearson's r = -0.553; p < 0.001). In contrast, vitamin D, vitamin B12, folic acid, ferritin, and lipid parameters (triglycerides, HDL, LDL, total cholesterol) showed no statistically significant and no clinically meaningful correlation with AMH, with all coefficients remaining below 0.20 regardless of transformation (all p > 0.05). After adjustment for age, every coefficient attenuated further towards the null (all |rpartial| < 0.10; all p ≥ 0.127), the largest being that of 25-hydroxyvitamin D (rpartial = 0.094, 95% CI -0.027 to 0.213). A sensitivity power analysis confirmed 80% power to detect an age-adjusted partial correlation of |r| = 0.172 and 91% power at |r| = 0.200. Conclusions: Age remains the principal determinant of ovarian reserve, while vitamin D, vitamin B12, folic acid, ferritin, and lipid parameters show no statistically significant or clinically meaningful association with AMH. These findings suggest that any biological influence of these micronutrients on ovarian reserve, if present, is markedly overshadowed by age-dependent follicular decline. Prospective studies incorporating longitudinal AMH measurements and standardized nutritional assessment are needed to further clarify these relationships.

PMID 42882033
Read full article →
PubMedMolecules (Basel, Switzerland)2026-10-16

A Dual-Functional Magnetic Nanoparticle for Rapid Extraction and Targeted Tumor Delivery of Tiancimycin.

Zhang Chengyu C, Zhong Peng P, Zhao Daxin D, Lv Yun Y et al.

Anthraquinone-fused enediynes (AFEs) are a class of microbial natural products with remarkable cytotoxicity and exhibit promising application prospects in tumor therapy. Taking tiancimycins (TNMs) as an example, this class of compounds holds great potential against triple-negative breast and liver cancers. However, the low production titers of AFEs in actinobacterial hosts make their enrichment and separation processes both cumbersome and costly. Therefore, the main objective of this study was to develop a rapid and reusable magnetic platform for TNM enrichment and recovery. Inspired by the pi-pi stacking interactions between AFEs and their natural binding proteins in the producing strains, this study designed and prepared alizarin- and folic acid-co-modified magnetic nanoparticles (PNMP-AZ-FA). On the one hand, these nanoparticles can directly and specifically adsorb TNMs from the crude extract of Streptomyces sp. CB03234-S, enabling efficient separation. On the other hand, the folic acid modification was explored as a proof-of-concept delivery element for drug-loaded nanoparticles in folate receptor (FR)-expressing tumor models. PNMP-AZ-FA showed loading capacities of 87.8 and 106.7 mg/g for TNM A and TNM D, respectively, and retained high adsorption performance during 20 repeated cycles. Animal experiment results demonstrated that the TNM-loaded nanoparticle (PNMP-AZ-FA@TNM A) improved antitumor activity under the tested conditions, especially in the FR-high KB model; however, receptor-dependent uptake, biodistribution, and pharmacokinetic validation are still required. In summary, this nanoparticle holds great application prospects in the rapid separation and acquisition of AFEs, while its tumor-delivery application should be regarded as preliminary evidence.

PMID 42883295
Read full article →
PubMedNutrients2026-10-16

Folic Acid Oversupplementation Alters Global DNA Methylation and Circadian Clock Gene Expression in FaDu Head and Neck Squamous Cell Carcinoma Cells: An Exploratory Study.

Faramarzi Garous Negin N, Lobanova Liubov L, Papagerakis Silvana S, Lieffers Jessica R L JRL et al.

Folic acid (FA), the synthetic form of folate (vitamin B9), is a vitamin involved in one-carbon metabolism, DNA synthesis, and DNA methylation. Because folate metabolism influences methyl donor availability, FA availability may affect circadian clock gene regulation through methylation-related or other metabolic mechanisms in head and neck squamous cell carcinoma (HNSCC). This exploratory study aims to determine whether FA oversupplementation influences cell viability and alters global DNA methylation, as well as the expression and methylation status of circadian clock genes in HNSCC cells. FaDu HNSCC cells were treated with 20 or 80 μM FA and compared with a no-added-FA (NF) reference condition. Cell viability was assessed using a CCK-8 assay after 48 and 72 h. For methylation and gene expression analyses, cells were synchronized with forskolin and treated with FA (20 or 80 μM) for 7 days. Global DNA methylation was measured using a 5-methylcytosine colorimetric assay. Following the NF and 80 μM FA treatment, cytosine-phosphate-guanine (CpG) island methylation in the BMAL1 and PER2 promoters, RNA expression, and protein levels were analyzed by bisulfite conversion followed by Sanger sequencing, qPCR, and ELISA. FA treatment significantly reduced cell viability at 48 h (20 μM, p < 0.05; 80 μM, p < 0.01) and 72 h (both concentrations p < 0.01). Global DNA methylation was modestly reduced, reaching statistical significance only in the 80 μM FA group (p < 0.05). No qualitative differences were observed in the promoter methylation of the analyzed CpG regions of BMAL1 and PER2 following 80 μM FA treatment. However, BMAL1 and PER2 mRNA expressions were significantly increased (p < 0.05), while protein levels showed non-significant upward trends following 80 μM FA treatment. These exploratory findings suggest that the observed transcriptional changes are unlikely to be explained by methylation changes within the analyzed promoter regions of BMAL1 and PER2. The mechanisms underlying these changes remain unclear and require further investigation.

PMID 42884632
Read full article →
PubMedMaterials (Basel, Switzerland)2026-10-16

Zinc Oxide Nanoparticles as Drug Delivery Tools.

Shirazi Amir Nasrolahi AN, Vadlapatla Rajesh R, Koomer Ajoy A, Tang Kimberly K et al.

Zinc oxide nanoparticles (ZnO-NPs) have emerged as promising inorganic nanocarriers for drug delivery due to their unique physicochemical properties, pH-responsive biodegradability, high surface area, and intrinsic biological activity. Their dissolution under acidic conditions enables controlled drug release within the tumor microenvironment and intracellular compartments, improving therapeutic selectivity while aiming to reduce off-target exposure. Surface functionalization with polyethylene glycol (PEG), chitosan, hyaluronic acid, and folic acid has further improved nanoparticle stability, prolonged circulation, and promoted receptor-mediated cellular uptake in targeted tissues. Beyond serving as drug carriers, ZnO-NPs exhibit intrinsic anticancer, antimicrobial, and anti-inflammatory activities, primarily through the generation of reactive oxygen species and controlled release of Zn2+ ions, which can contribute to activity in addition to that of the loaded drug. Despite promising preclinical results, challenges continue to limit clinical translation of ZnO-NP-based drug delivery systems, including reproducible large-scale synthesis, long-term colloidal stability and biosafety, pharmacokinetic behavior, and regulatory requirements. Continued optimization of nanoparticle engineering, functionalization, and in vivo validation is essential for advancing ZnO-NPs toward clinical use. This review summarizes the synthesis methods, physicochemical properties, functionalization strategies, and biomedical applications of ZnO-NPs, and discusses remaining challenges and future clinical perspectives.

PMID 42882621
Read full article →
PubMedFoods (Basel, Switzerland)2026-10-16

Protein Composition and Postprandial Aminoacidemia of Biscuits Fortified with Brewer's Spent Grain and Fermented Brewer's Spent Grain in Individuals with Metabolic Syndrome.

Leong Zi Ning ZN, Xu Yujing Y, Chen Jialin J, Chang Yidan Y et al.

Brewer's spent grain (BSG), the main side-stream of beer brewing, is an abundant and low-cost source of plant protein with limited digestibility. Fermentation pre-treatment may improve protein quality by altering amino acid composition and increasing protein accessibility. This study investigated whether the solid-state fermentation of BSG with Rhizopus oligosporus could improve amino acid composition and further elicit a greater postprandial amino acid response after the consumption of BSG-incorporated biscuits in adults with metabolic syndrome (MetS). Control biscuits (100% wheat flour) and biscuits with a 30% substitution of autoclaved BSG and fermented BSG were prepared. Compositional improvements were evaluated via an analysis of total and free amino acids and the amino acid score calculated against adult indispensable amino acid requirements. Fifteen adults with MetS then consumed 90 g of each biscuit in a randomised, double-blind, crossover trial, with postprandial plasma amino acids assessed over 120 min. Incorporating BSG increased the total amino acid content in biscuits, while fermentation further increased free amino acid content. The lysine amino acid score also increased from 0.57 (Control) to 0.81 (fermented BSG). Despite these compositional improvements, postprandial total and essential amino acid responses did not differ between biscuits, indicating a disconnect between improved protein composition and postprandial amino acid responses in individuals with MetS.

PMID 42883665
Read full article →
PubMedThe Journal of small animal practice2026-10-16

Urinary liver-type fatty acid-binding protein in cats with lower urinary tract disease.

Culha N N, Acar A A, Ulutas B B, Dinler Ay C C

The aim of this study was to evaluate urinary liver-type fatty acid-binding protein levels in both obstructive and non-obstructive feline lower urinary tract disease. In addition, urinary liver-type fatty acid-binding protein levels were investigated in cats experiencing short-term (<36 hours) and long-term (≥36 hours) urethral obstruction. The study included 32 cats, classified into two main groups: cats with feline lower urinary tract disease (n = 24) and healthy controls (n = 8). The feline lower urinary tract disease group was subdivided into obstructive (n = 16) and non-obstructive (n = 8) forms. The obstructive group was further divided based on urethral obstruction duration into short-term (n = 8) and long-term (n = 8) sub-subgroups. Serum creatinine, blood urea nitrogen and potassium were measured in blood samples. Urinary liver-type fatty acid-binding protein and urinary creatinine concentrations were measured in urine supernatant samples. Urinary liver-type fatty acid-binding protein concentrations were indexed to urinary creatinine and expressed as the urinary liver-type fatty acid-binding protein/creatinine ratio. The mean urinary liver-type fatty acid-binding protein/creatinine values of cats with obstructive feline lower urinary tract disease were statistically higher than those in cats with non-obstructive feline lower urinary tract disease and healthy controls. The difference between the mean urinary liver-type fatty acid-binding protein/creatinine values of cats with long-term and short-term obstruction was not statistically significant. In addition, moderately positive correlations were calculated between urinary liver-type fatty acid-binding protein/creatinine and serum creatinine (r = .646; P < .001; 95% CI = 0.264 to 0.863) and between urinary liver-type fatty acid-binding protein/creatinine and blood urea nitrogen (r = .549; P < .01; 95% CI = 0.081 to 0.791) in the study population. This study is the first to report urinary liver-type fatty acid-binding protein/creatinine in cats with feline lower urinary tract disease. The findings suggest that urinary liver-type fatty acid-binding protein/creatinine may serve as a potential biomarker for identifying post-renal acute kidney injury in cats with obstructive feline lower urinary tract disease, particularly in long-term obstructive cases.

PMID 42885408
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about benfotiamine + folic acid + benzamine